Precede Biosciences
Precede Biosciences is a precision medicine company that has developed a first-in-class comprehensive epigenomic liquid biopsy platform. This platform profiles circulating chromatin and the DNA methylome from just 1mL of plasma, providing unprecedented resolution into disease-defining biology by analyzing ~20,000 gene promoters, ~1 million gene enhancers, and ~50,000 CpG islands. Their technology enables the detection of activation status of therapeutically actionable genes and pathways, facilitating minimally invasive diagnosis and treatment tailored to the biology of diseases such as cancer and multiple sclerosis. Precede partners with drug developers and academic researchers to improve drug development success rates and to enable biology-based decision-making in clinical practice. The company is led by experts in liquid biopsy development, computational biology, epigenomics, and translational sciences, and has presented data at major conferences including AACR, ASCO, SABCS, and ESMO, demonstrating the platform's ability to resolve gene expression for thousands of tumor-specific genes and to characterize mechanisms of response and resistance to therapies.
Precede Biosciences
Precede Biosciences is a precision medicine company that has developed a first-in-class comprehensive epigenomic liquid biopsy platform. This platform profiles circulating chromatin and the DNA methylome from just 1mL of plasma, providing unprecedented resolution into disease-defining biology by analyzing ~20,000 gene promoters, ~1 million gene enhancers, and ~50,000 CpG islands. Their technology enables the detection of activation status of therapeutically actionable genes and pathways, facilitating minimally invasive diagnosis and treatment tailored to the biology of diseases such as cancer and multiple sclerosis. Precede partners with drug developers and academic researchers to improve drug development success rates and to enable biology-based decision-making in clinical practice. The company is led by experts in liquid biopsy development, computational biology, epigenomics, and translational sciences, and has presented data at major conferences including AACR, ASCO, SABCS, and ESMO, demonstrating the platform's ability to resolve gene expression for thousands of tumor-specific genes and to characterize mechanisms of response and resistance to therapies.
TL;DR
What they do: Develop a comprehensive epigenomic liquid biopsy that profiles circulating chromatin and the DNA methylome from 1 mL of plasma to infer gene expression and pathway activity.
Customers / partners: Drug developers and academic researchers (platform offered as RUO service).
Funding signal: Series A (~$57M) in Oct 2023; announced Series B equity plus strategic credit facility (total $83.5M) in Jan 2026.
Origin: Founded from research begun at Dana-Farber Cancer Institute; incubated via 5AM Ventures' 4:59 Initiative.
Company Overview
Problem Domain
Precision medicine diagnostics; liquid biopsy for cancer and other diseases (e.g., multiple sclerosis) to inform drug development and clinical decision-making.
Industry
Biotechnology / Precision Diagnostics
Funding Track Record
57000000.00
Reported participation from Illumina Ventures, Bristol-Myers Squibb, Qatar Investment Authority, Osage University Partners, Binney Street Capital and others.
63500000.00
Announced alongside a $20,000,000 strategic non-dilutive credit facility; new investors named include Labcorp Venture Fund, UPMC Enterprises, Mirae Asset, 28 Capital, and Alexandria Venture Investments.
Investor Signal
“Includes strategic and corporate investors (e.g., Illumina Ventures, Bristol-Myers Squibb, Labcorp Venture Fund) alongside venture investors (e.g., 5AM Ventures).”